CD274 and non-small cell lung carcinoma: Some studies have demonstrated no significant improvement in the treatment response or prognosis resulting from the addition of SBRT to PD-1/PD-L1 inhibitors in advanced NSCLC patients compared with the use of PD-1/PD-L1 inhibitors alone (26, 27).